Background: Tobacco use causes at least 12 types of cancer and is the leading preventable cause of cancer.
Introduction
Tobacco use remains the leading preventable cause of disease and death in the United States, resulting in 480,000 deaths and more than $300 billion in direct health care expenditures and productivity losses each year (1) . More than 70 carcinogens have been identified in tobacco smoke and 28 in smokeless tobacco products (2). Cigarette smoking causes cancers throughout the body, including cancers of the oral cavity and pharynx; esophagus; stomach; colon and rectum; liver; pancreas; larynx; lung, bronchus, and trachea; kidney and renal pelvis; urinary bladder; and cervix, as well as acute myeloid leukemia (1, 2) . Additionally, the use of smokeless tobacco (snuff and chewing tobacco) causes cancers of the oral cavity, pancreas and esophagus (2,3), cigar use causes cancers of the oral cavity, pharynx, esophagus, larynx, and lung (4), and secondhand smoke exposure causes lung cancer (2,5).
Data compiled for the United States Cancer Statistics (USCS) dataset were used to summarize disparities in incidence and death rates and trends during 2004-2013 for cancers that can be caused by tobacco use (tobacco-related cancers). In this report, tobacco-related cancers were defined as those classified by the U.S. Surgeon General as causally related to cigarette smoking (1); those classified also encompass cancers related to other tobacco products (2-4). Trends in all-cancer, lung cancer, and tobacco-related cancer death rates were also examined for 1970-2014.
Methods
The USCS dataset is a compilation of data from multiple sources and is used to report the official federal cancer statistics through the USCS web-based report (6) . The USCS dataset includes cancer incidence data from the CDC's National Program of Cancer Registries (NPCR) and the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) program and cancer mortality data from the National Vital Statistics System (NVSS) (6) . Data on new cases of cancer diagnosed during [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] were obtained from population-based cancer registries affiliated with NPCR and SEER programs in each state, the District of Columbia (DC), and Puerto Rico. Data from Puerto Rico met USCS publication criteria for [2009] [2010] [2011] [2012] [2013] , and data from DC and all states except Nevada met USCS publication criteria for 2004-2013; consequently, incidence data in this report cover 99% of the U.S. population.* Cancer site for cases was classified by anatomic site and histology. † Only cases of invasive cancer were included, except for urinary bladder cancer, which also included in situ tumors.
Data on cancer deaths during 1970-2014 were based on death certificate information reported to state vital statistics offices and compiled into a national file through NVSS. The underlying cause of death was selected according to the version of the International Classification of Diseases (ICD) codes and selection rules in use at the time of death (ICD-6 to ICD-10) and categorized according to SEER site groups to maximize comparability with ICD for Oncology (ICD-O) classifications. § Population estimates for rate denominators were annual race-, ethnicity-, and sex-specific county population estimates from the U.S. Census, as modified by NCI and aggregated to the state and national level. ¶ Average annual incidence  and death rates for 2004-2008 and 2009-2013 per 100,000 persons were age-adjusted to the 2000 U.S. standard population; in this analysis, death rates were limited to data through 2013, the most recent year for which incidence data were available. Annual percentage change (APC) was used to quantify changes in rates from 2004-2013 and was calculated using least squares regression. Rates and trends were estimated by sex, age, race, ethnicity, U.S. Census region, quartiles of county-level educational attainment (percentage of persons aged ≥25 years with at least a bachelor's degree), quartiles of county-level poverty (percentage of persons living below poverty threshold), and county-level rural/urban continuum.** State-specific ageadjusted tobacco-related cancer incidence rates and APCs were mapped using quartiles as cut points. Cancer deaths attributable to cigarette smoking among adults aged ≥35 years were based on recent estimates of smoking-attributable fractions (7). Annual age-adjusted rates for all-cancer, lung cancer, and tobacco-related cancer deaths were examined for 1970-2014. The number of tobacco-related cancer deaths averted was estimated by subtracting the actual number of deaths each year through 2014 from the number expected if tobacco-related cancer death rates had remained at the peak levels (during 1990, among men, and 1995, among women).
Results
During 2009-2013 approximately 660,000 persons received a diagnosis of a tobacco-related cancer each year in the United States, and 343,000 persons died from these cancers ( Table 1) . Tobacco-related invasive cancer incidence declined 1. The tobacco-related cancer incidence rate was 1.7 times higher among males (250 per 100,000) than among females (148 per 100,000), as was the death rate (131 per 100,000 males vs. 76 per 100,000 females). Both incidence and death rates of tobaccorelated cancer decreased faster during 2004-2013 among males (-1.5% and -1.8%) than among females (-1.2% and -1.4%).
Tobacco-related cancer incidence and death rates increased with age, and one third of cases and two fifths of deaths occurred among persons aged ≥75 years (Table 1 ). Tobacco-related cancer incidence and death rates were highest, but decreased fastest, among blacks compared with other racial/ethnic groups. Tobacco-related cancer incidence and death rates were highest, and incidence decreased slowest, in counties with lowest educational attainment or highest poverty, and were lowest, and decreased fastest, in metropolitan areas with ≥1 million population. * Cancer registries demonstrated that cancer incidence data were of high quality by meeting the six USCS publication criteria: 1) case ascertainment ≥90% complete; 2) ≤5% of cases ascertained solely on the basis of death certificate; 3) ≤3% of cases missing information on sex; 4) ≤3% of cases missing information on age; 5) ≤5% of cases missing information on race; and 6) ≥97% of registry's records passed a set of single-field and inter-field computerized edits that test the validity and logic of data components. * Tobacco-related cancers include cancers of the oral cavity and pharynx; esophagus; stomach; colon and rectum; liver; pancreas; larynx; lung, bronchus, and trachea; cervix; kidney and renal pelvis; urinary bladder; and acute myeloid leukemia. † Per 100,000 persons, age-adjusted to the 2000 U.S. standard population. § Trends were measured with annual percentage change (APC) in rates and were considered to increase or decrease if p<0.05; otherwise trends were considered stable. Trends marked with § were significant at p<0.05. ¶ Cancer cases were compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (covering approximately 99% of the U.S. population). Cancer deaths are from the National Vital Statistics System; mortality data are available through 2014 but are shown through 2013 for comparability with incidence data for which the most recently available data are from 2013. ** Racial categories are not mutually exclusive from Hispanic ethnicity. Rates are not presented for patients with unknown or other race or unknown ethnicity.
Incidence rates by ethnicity exclude data from Virginia because a large percentage of these cases were missing information on ethnicity. By region, tobacco-related cancer incidence and death rates were lowest in the West and decreased most slowly in the Midwest (Table 1) . Incidence rates of tobacco-related cancer ranged two-fold among states with available data, from 248 per 100,000 persons in Kentucky to 130 per 100,000 (Utah) and 126 per 100,000 (Puerto Rico) (Figure 1 ). The incidence of tobacco-related cancer decreased significantly in 44 states with available data (-0.4% to -2.4%), and did not change significantly in five states and DC (Figure 1) .
By cancer site, incidence and death rates were highest for lung cancer, which accounted for about one third of tobacco-related cancer cases and almost one half of tobacco-related cancer deaths (Table 2 ). For each cancer site (except cervix), incidence and death rates were higher among males than females. In 2009-2013, approximately 101,300 men and 65,700 women died of cigarette smoking-attributable cancers each year. Lung cancer caused most of these deaths and had the highest cigarette smoking-attributable fraction (80%).
All cancer death rates peaked in 1990 among males and in 1991 among females (Figure 2 ). About 60% of the decrease in all cancer death rates among males was due to decreases in tobacco-related cancers, which also peaked in 1990. Among females, tobacco-related cancer death rates began to decline in 1995 and accounted for 40% of the decrease in all cancer death rates. Due to reductions in tobacco-related cancers, approximately 1,025,000 tobacco-related cancer deaths were averted among men since 1990, and 242,000 among women since 1995.
Conclusions and Comments
Tobacco-related cancer death rates in the United States have been declining since 1990 among men and since 1995 among women and continued to decline through 2014. These declines reflect the implementation of evidence-based tobacco prevention and control interventions, along with improvements in cancer prevention, detection, and treatment (8) . Since tobaccorelated cancer death rates began to decline, approximately 1.3 million tobacco-related cancer deaths have been averted. However, too many preventable tobacco-related cancer cases and deaths still are occurring. This analysis found that during 2009-2013, cigarette smoking caused 167,000 cancer deaths each year, about 30% of the 577,000 cancer deaths each year (6) . Most of these deaths were from lung cancer, the leading cause of cancer deaths for both men and women (6) . Furthermore, exposure to secondhand smoke could account for an additional 7,300 lung cancer deaths among nonsmokers (1) .
At least half of persons who continue to smoke are expected to die from a tobacco-related disease, although tobacco cessation significantly decreases this risk (9) . Therefore, among the 36.5 million people in the United States who currently smoke cigarettes (10), about 18.25 million might die prematurely from a tobacco-related disease, including 6 million from cancer, unless stategies are implemented to help them quit. Many tobacco-related cancers could be prevented by reducing tobacco use through sustained, comprehensive, evidence-based tobacco prevention and control interventions (8) . These interventions include increased tobacco product prices, implementation and enforcement of comprehensive smoke-free laws, aggressive mass media campaigns, and promotion of smoking cessation resources proven to help users quit tobacco use (11) . States that have invested more fully in tobacco prevention and control programs generally have experienced larger declines in youth and adult smoking prevalence, decreases in lung cancer, and reduced tobacco-related health care costs (11) . A recent report found that smoking-attributable cancer mortality varied by state from 17% to 34% and suggested that disparities in cancer deaths among states can be explained in part by differences in smoking prevalence (12) . In this report, tobacco-related cancers declined across most demographic groups, but not at the same pace, and not in all states. Funding state tobacco control programs at CDC-recommended levels can accelerate progress toward reducing tobacco-related cancers (11) .
Although many factors might contribute to tobacco-related cancer disparities, they generally align with disparities in cigarette smoking prevalence by sex, geography, and socioeconomic status (10) . Identifying and eliminating tobacco-related disparities is a goal of CDC's National Tobacco Control Program, which provides funding and technical support to state and territorial health departments. † † CDC also funds the Consortium of National Networks to Impact Populations Experiencing Tobacco-Related and Cancer Health Disparities, which seeks to advance tobacco use prevention and cancer prevention among persons at highest risk for tobacco use. § § Preventive services recommended by the U.S. Preventive Services Task Force relevant to tobacco-related cancers include tobacco cessation counseling and treatment as well as screening for cervical, colorectal, and lung cancers to help detect these diseases at an early, and often treatable, stage. ¶ ¶ Screening also can detect precancerous cervical lesions and precancerous colorectal polyps which can be treated to prevent progression to cancer. Vaccination against hepatitis B virus and human papillomavirus, as recommended by the Advisory Committee for Immunization Practices, could prevent some cancers (liver and cervix) to which both tobacco and infectious agents can contribute.*** The Affordable Care Act increased access to recommended preventive services through expanded insurance coverage and eliminating cost-sharing; however, coverage and barriers to treatment vary by type of insurance and state (13, 14) . CDC's National Comprehensive Cancer Control Program funds states, DC, tribes and territories to work through state and local level cancer coalitions to ensure access to these early detection and treatment services, implement evidence-based programs to prevent cancer, and support cancer survivorship activities. † † † Federal initiatives can help reduce tobacco use and tobaccorelated cancers. For example, a 1997 Executive Order established a smoke-free environment for federal employees and members of the public visiting or using federal facilities by prohibiting smoking of tobacco products in all interior space owned, rented, or leased by the executive branch of the Federal Government. § § § A key priority of the Cancer Moonshot, a recently launched large-scale federal initiative, is to accelerate understanding of cancer and promote its prevention. ¶ ¶ ¶ To help inform the Moonshot initiative, the Blue Ribbon Panel, a working group of the National Cancer Advisory Board, recommended implementation research to achieve wider adoption of existing evidence-based tobacco control, cancer prevention, and screening programs, especially to reach groups with the largest cancer disparities.**** The findings in this report are subject to at least five limitations. First, rates among some racial and ethnic groups might be underestimated because race and ethnicity data are ascertained from medical records and death certificates and might be subject to misclassification (15) . Second, while the most recent Surgeon General's Report was used to define tobacco-related cancers, this might underestimate the true burden because evidence is still accumulating that tobacco use might cause additional cancers (1) . The burden also might be underestimated because this report did not include the contribution of † Tobacco-related cancers include oral cavity and pharynx; esophagus; stomach; colon and rectum; liver; pancreas; larynx; lung, bronchus, and trachea; cervix; kidney and renal pelvis; urinary bladder; and acute myeloid leukemia. ¶ ¶ ¶ https://www.whitehouse.gov/CancerMoonshot. **** https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative. *** http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html and http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html. † † † http://www.cdc.gov/cancer/ncccp/index.htm. § § § https://www.archives.gov/federal-register/executive-orders/1997.html. tobacco use to adverse health outcomes among cancer patients such as poorer response to cancer treatment, higher treatmentrelated toxicity, higher risks of developing subsequent cancers, and higher risk of dying (1) . Third, the smoking-attributable fraction for cancer deaths was based only on cigarette smoking and did not include harms related to other forms of tobacco use or secondhand smoke (3) (4) (5) . Fourth, because information about tobacco use is not routinely collected by cancer registries or on death certificates, cancer cases and deaths included in this analysis might or might not be in persons who used tobacco. Fifth, cancers can be caused by many different factors, including tobacco use; therefore, the number of cases and trends in tobacco-related cancers might also be affected by changes in other risk factors, screening, or treatment.
Incidence and mortality from tobacco-related cancer declined during 2004-2013, continuing a longer-term trend. Comprehensive cancer control efforts, including evidencebased tobacco control interventions, can reduce tobacco use and the burden of cancer in the United States.
